Compared with injectable contraceptive norethisterone enanthate and combined oral contraceptive pills, contraceptive vaginal ring lowered cervical frequencies of Th17 cells, which may affect HIV risk stratification.
Compared to nonhormonal contraception, hormonal contraception appears to pose a greater risk for increased seizure frequency in women with epilepsy.
The vaginal ring releases on average 0.12mg/d of etonogestrel, a progestin, and 0.015mg/d of ethinyl estradiol, an estrogen.
One in three women of reproductive age have a chronic condition that could compromise their health or lead to adverse outcomes during pregnancy, yet few use the most effective forms of contraception.
Symptoms of depression are associated with oral contraceptive use in 16-year-old girls compared with adolescents and young women up to 25 years of age.
The FDA has approved the use of Liletta (levonorgestrel-releasing intrauterine system; Allergan and Medicines360) for the prevention of pregnancy for up to 6 years. Previously, the progestin-containing intrauterine device was indicated for up to 5 years of use.
Bayer announced the submission of a supplemental New Drug Application to the Food and Drug Administration (FDA) for the intrauterine device.
Amphora is a non-hormonal vaginal gel that regulates vaginal pH in order to prevent pregnancy.
The authors note that one reason for inconsistent or nonuse of contraception is barriers to access.
Planned Parenthood is withdrawing from the U.S. government’s family planning program.
